Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer

被引：26
作者：
Fedele, Palma [1 ]
Orlando, Laura [1 ]
Schiavone, Paola [1 ]
Calvani, Nicola [1 ]
Caliolo, Chiara [1 ]
Quaranta, Annamaria [1 ]
Nacci, Angelo [1 ]
Cinieri, Saverio [1 ,2 ]
机构：
[1] A Perrino Hosp, Med Oncol & Breast Unit, I-72100 Brindisi, Italy
[2] European Inst Oncol, Div Med Oncol, Milan, Italy
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2015年 / 94卷 / 03期
关键词：
Targeted agents; Metastatic breast cancer; Endocrine therapy; Endocrine resistance; Next generation sequencing technologies; RANDOMIZED PHASE-II; EVEROLIMUS PLUS EXEMESTANE; PLACEBO-CONTROLLED TRIAL; POSTMENOPAUSAL WOMEN; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; DOUBLE-BLIND; PROGESTERONE-RECEPTOR; AROMATASE INHIBITORS; PD; 0332991;
D O I：
10.1016/j.critrevonc.2015.01.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Endocrine therapy is the recommended systemic therapy for hormone receptor (HR) positive metastatic breast cancer (MBC). However so far the limited number of endocrine agents and the onset of endocrine resistance have severely limited the therapeutic options for this patients. In the last years many targeted agents have been investigated to prevent or overcome endocrine resistance; only a few of them have been found effective in HR positive MBC, such as everolimus, CK4/6 inhibitors and HDAC inhibitors. Furthermore, translational medicine studies using next generation sequencing technologies have evaluated genetic variations of a broad panel of cancer-related genes and explored their correlations with targeted agents benefit. In some studies predictive biomarkers have been identified and many ongoing studies are evaluating the efficacy of targeted drugs in HR positive MBC patients selected for biomarkers or stratified by pathways amplification. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：291 / 301
页数：11
相关论文
共 57 条
  • [1] An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells
    Aesoy, Reidun
    Sanchez, Betzabe Chavez
    Norum, Jens Henrik
    Lewensohn, Rolf
    Viktorsson, Kristina
    Linderholm, Barbro
    [J]. MOLECULAR CANCER RESEARCH, 2008, 6 (10) : 1630 - 1638
  • [2] [Anonymous], ASCO ANN M P
  • [3] [Anonymous], ASCO M, DOI DOI 10.1200/JCO.2010.28.15_SUPPL.3060
  • [4] Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance
    Arpino, Grazia
    Wiechmann, Lisa
    Osborne, C. Kent
    Schiff, Rachel
    [J]. ENDOCRINE REVIEWS, 2008, 29 (02) : 217 - 233
  • [5] Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
    Bachelot, Thomas
    Bourgier, Celine
    Cropet, Claire
    Ray-Coquard, Isabelle
    Ferrero, Jean-Marc
    Freyer, Gilles
    Abadie-Lacourtoisie, Sophie
    Eymard, Jean-Christophe
    Debled, Marc
    Spaeth, Dominique
    Legouffe, Eric
    Allouache, Djelila
    El Kouri, Claude
    Pujade-Lauraine, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) : 2718 - 2724
  • [6] Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial
    Bartlett, John M. S.
    Brookes, Cassandra L.
    Robson, Tammy
    van de Velde, Cornelis J. H.
    Billingham, Lucinda J.
    Campbell, Fiona M.
    Grant, Margaret
    Hasenburg, Annette
    Hille, Elysee T. M.
    Kay, Charlene
    Kieback, Dirk G.
    Putter, Hein
    Markopoulos, Christos
    Kranenbarg, Elma Meershoek-Klein
    Mallon, Elizabeth A.
    Dirix, Luc
    Seynaeve, Caroline
    Rea, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (12) : 1531 - 1538
  • [7] Baselga J, 2011, EUR MULT CANC C EMCC
  • [8] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
    Baselga, Jose
    Campone, Mario
    Piccart, Martine
    Burris, Howard A., III
    Rugo, Hope S.
    Sahmoud, Tarek
    Noguchi, Shinzaburo
    Gnant, Michael
    Pritchard, Kathleen I.
    Lebrun, Fabienne
    Beck, J. Thaddeus
    Ito, Yoshinori
    Yardley, Denise
    Deleu, Ines
    Perez, Alejandra
    Bachelot, Thomas
    Vittori, Luc
    Xu, Zhiying
    Mukhopadhyay, Pabak
    Lebwohl, David
    Hortobagyi, Gabriel N.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) : 520 - 529
  • [9] Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
    Baselga, Jose
    Semiglazov, Vladimir
    van Dam, Peter
    Manikhas, Alexey
    Bellet, Meritxell
    Mayordomo, Jose
    Campone, Mario
    Kubista, Ernst
    Greil, Richard
    Bianchi, Giulia
    Steinseifer, Jutta
    Molloy, Betty
    Tokaji, Erika
    Gardner, Humphrey
    Phillips, Penny
    Stumm, Michael
    Lane, Heidi A.
    Dixon, J. Michael
    Jonat, Walter
    Rugo, Hope S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2630 - 2637
  • [10] FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
    Bergh, Jonas
    Jonsson, Per-Ebbe
    Lidbrink, Elisabet Kerstin
    Trudeau, Maureen
    Eiermann, Wolfgang
    Brattstrom, Daniel
    Lindemann, Justin P. O.
    Wiklund, Fredrik
    Henriksson, Roger
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1919 - 1925
123456